The Staffing and Recruiting Experts

Serving all your contract and permanent placement needs

How Can We Help You?

Find the Right Job

Your job search will start and end here

Search Jobs Now?

STAFFING AND RECRUITING SINCE 2002 we’ve been building our firm by providing staffing and recruiting solutions throughout New England, Central, West Coast, and Mid-Atlantic regions. If you are looking for a full-service staffing firm with a solid reputation and a service team that can find highly specialized candidates for any scale staffing projects, let’s start a conversation. LEARN MORE

Top Staffing, Recruiting, and Employment Agency

IT engineer

Staffing & Placements

  • Access skilled professionals who make a positive impact on outcomes—starting on day one.

  • We cover a wide range of industries: Technology, Clinical, Pharmaceutical/Biotech, Medical Device, Banking, Finance, Telecommunications, Electronics, Admin/Clerical, Health and Human Services, and Retail

  •  Cutting-edge recruiting database with over 750,000 candidates

  • Contract, contract-to-permanent, and contingency-based/direct hire options.

A&A Search Staffing: Putting You First

A&A Search Staffing is driven – just as hard as you are – to deliver effective, efficient and successful results. Since 2002, we’ve built our industry-leading recruitment philosophy on providing superior candidates who hit the ground running. Serving clients in New England, Central, West Coast, and Mid-Atlantic regions. We’re committed to providing staffing and recruiting solutions that are tailored to your company, specific industry, and culture…all to meet your staffing expectations. Let us put you first. Contact or call us at 603.910.6061.

9 + 12 =

Staffing and Placement News & Resources

The Hazards of Office Wellness Programs

HR & Management

According to Jan Wieczner of The Wall Street Journal, approximately 90% of employers provide health care programs with wellness incentives or financial rewards to employees. In 2008, that number was 57%. The programs are designed to encourage employees to take action towards improved health that will reduce health care expenses for employers. A survey by Fidelity Investments and the National Business Group reveals that the average incentive for employees has doubled from $260 in 2009 to $521 today. In some cases, penalties are applied.   While it should be desirable for an employer to care about an employee’s wellbeing, penalizing an employee for personal habits or overall lifestyle choices seems misplaced. Although some workplace programs can be considered effective, Leah Binder of Forbes magazine outlined some of the disadvantages of ineffective worksite wellness programs in an article dated April 2014. Employees are often asked to complete online questionnaires that delve into personal habits and health status; refusal can mean penalties in the range of $1,000 in some cases. This renders such programs possible privacy, health, and business risks that can alienate employees. There is a danger in informing employees that they should stop smoking, eat more vegetables, and exercise. Similarly, an employer that demands 50 hour work weeks and who indirectly instructs an employee to take up yoga and get a heart check is  ironic, patronizing, and unlikely to be taken seriously. It is debatable whether wellness programs save money for the employer. The programs themselves cost money to establish and the additional health screenings, treatment, and the education services are costly too. Additionally, employees could be subject to... read more

How Is the Internet of Things beginning to Drive CRM Investments?

General IT

The Internet of Things (IoT) refers to objects that support Internet structures. For example, radio-frequency identification and tagging, such as the use of bar codes, allows computers to collect big data. This technology is advancing so rapidly that effectively managing big data is a challenge. The potential for mining and applying such intelligence with respect to CRM is a focus for innovative IT companies. IT News contributor, J.D. Sartain, emphasizes that customer relationship management (CRM) technology is embracing mobile technology, social media, and analysis tools such as web analytics. Companies are eager to invest in multichannel technology products that will enhance customer engagement and facilitate customer loyalty to brands and products. CRM encompasses cloud technology, big data technology and, more recently IoT. IoT is poised to alter industries such as hospitality, construction, and healthcare as sensors and identifiers will facilitate superior performance from customer service centers and marketing groups. Already, CRM processes monitor social network platforms such as Facebook and LinkedIn to provide data and customer information for innovation. New mobile gadgets, the tablet is the most recent example, are challenging the IT community as it struggles to keep up with customer demand for service and support. Smartphone Internet connections are predicted to exceed PC connections by the end of 2014. Big data is being collected and is available for marketing purposes, but there is a lack of skills and resources to analyze and apply the plethora of intelligence that is available. The race is on among IT companies to develop the appropriate tools and expertise to exploit this intelligence. Cloud, social, mobile and big data technology are demanding... read more

What were the Top Experimental Cancer Drugs in 2013?

ClinLab Staffing

Many pharma companies are developing new cancer treatment drugs to meet the demand by doctors and patients. According to FierceBiotech, regulators are helping pharmas bring these new treatments to market by reducing the required clinical trial phases for certain promising experimental drugs. The leading experimental cancer drugs for 2013 were outlined by FierceBioTech. Ibrutinib (PCI-32765) is currently under development by Pharmacyclics and Johnson & Johnson to treat B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma. The drug was approved by the US FDA in November 2013. Pharmacyclics is now valued at over $5 billion. Nivolumab (BMS-936559), under development by Bristol-Myers Squibb, is a leading immunotherapy. It functions with immune responses to bolster attacks on cancer and tumors. Bristol-Myers has rights to both drugs following a 2009 buyout of Medarex for $2.4 billion. Pfizer’s palbociclib (PD-0332991) is promising in the treatment of breast cancer and can be taken in combination with the established drug, Novartis’s Femara. Palbociclib is also being considered for the treatment of ovarian cancer, multiple myeloma, and acute lumphoblastic leukemia. Estimated potential annual sales are $5 billion. Obinutuzumab (GA101) is under development by Roche Glycart. It is an anti-CD20 antibody that is designed to treat leukemia and other blood cancers. It will compete with Rituxan by Biogen Idec. Early results in testing show that cancers remained stable for 23 months and tumors shrank by 76 percent. Biogen Idec has rights to 35 percent of the drug after an agreement was reached with Roche’s Genentech, which shared the R&D expenses. Lambrolizumab (MK-3475) by Merck treats melanoma. In 85 out of 132 patients, there was a 51 percent response rate and a nine... read more